Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based technology and
products to the worldwide life sciences and other industries, today announced
its entry into a contract services agreement with a multi-billion
biotherapeutics company to enhance the manufacturing process of one of their
candidate protein drugs. Per the update, the manufacturing of therapeutic
proteins can be a complex and challenging process, and PBI’s BaroFold(TM)
technology platform offers a unique and cost-effective way to address major
challenges. “The BaroFold platform can be applied to the development and
production of many different therapeutic proteins, can improve product safety,
and is scalable and practical for standard bioprocess environments,” PBIO Chief
Science Officer Dr. Alexander Lazarev said in the news release. “Moreover, it
offers ways to reduce or eliminate the use of aggressive chemicals in the
protein manufacturing process. Thus, we believe this unique technology platform
can help biopharmaceutical companies create and manufacture high quality novel
protein therapeutics and biosimilars, lower the cost of existing formulations,
and help protect our environment.”
To view the full press release, visit http://ibn.fm/EHHhI
About Pressure BioSciences Inc.
Pressure BioSciences (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions for
the worldwide life sciences industry. The company’s products are based on the
unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control biomolecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil and plant biology, forensics and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired PreEMT technology from BaroFold
Inc. to allow entry into the biologics contract research services sector, and
(2) the use of its recently patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher
quality, homogenized, extended shelf-life or room temperature stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
